Providers

Yale New Haven Hospital’s reorganization of its sickle cell disease program led patients to report feeling better off and needing fewer hospitalizations. However, the change left some with the disease still feeling unsatisfied.

In the primary analysis of a phase 3 study, ruxolitinib reduced spleen length and symptoms in patients with myelofibrosis, according to results published in British Journal of Haemotology.

Researchers found that patients with idiopathic pulmonary fibrosis (IPF) are at increased risk of developing several forms of cancer compared with the general population.

Just like in clinical trials, a real-world analysis of patients with psoriatic arthritis who were treated with secukinumab achieved minimal disease activity, as well as other improvements.

Prevention and early screening efforts need to be stepped up for patients with acute heart failure who contract pneumonia while hospitalized.

Krisda H. Chaiyachati, MD, MPH, MSHP, discusses the study he co-wrote entitled “Economic Outcomes of Insurer-Led Care Management for High-Cost Medicaid Patients.”

Tisagenlecleucel, sold as Kymriah by Novartis, met its primary end point of complete response rate (CRR) in an interim analysis of a phase 2 study for relapsed or refractory follicular lymphoma (FL).

Patricia Salber, MD, MBA, of The Doctor Weighs In, and Sandeep “Bobby” Reddy, MD, an oncologist at Harbor-UCLA Medical Center and chief medical officer of NantHealth, discuss the clinical care of patients with cancer in the age of COVID-19.

The coronavirus disease 2019 (COVID-19) vaccines that are leading the pack are utilizing a new vaccine technology that has never been approved for human use by the FDA. As a result, there are a lot of unknowns.

Evidence may support a greater comorbidity burden among patients with heart failure with preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF), although this finding was shown to be worse among women with HFpEF.

The ruling reversed a lower court ruling regarding the drug discount program for hospitals that serve patients covered by Medicaid.

During the coronavirus disease 2019 (COVID-19) pandemic, clinics have closed to varying degrees. As clinics look to reopen or welcome back patients after a COVID-19 infection, the American College of Rheumatology (ACR) has released advice on strategies for reopening practices as the pandemic continues.

Patients with myeloproliferative neoplasms (MPNs) have high disease burden, and management of their disease can vary widely to include watchful waiting, phlebotomy, or drug therapy.

Patients who have both skin and joint symptoms with psoriatic arthritis have greater disease burden and worse quality of life compared with patients who have joint-only involvement.

The race for a coronavirus disease 2019 (COVID-19) vaccine is one of the most urgent public health challenges, with multiple vaccine candidates entering phase 3 trials and case counts around the world steadily climbing. MJH Life Sciences™ will host a free webinar with the top minds in infectious disease, virology, and vaccinology to discuss the latest trial information on vaccines.

In children with inflammatory rheumatic diseases, tocilizumab can cause serious adverse events (AEs), with children who were younger at disease onset and at time of tocilizumab initiation especially affected.

The researchers noted that these results can help inform therapeutic decision making and identify opportunities to address barriers to disease-modifying drug (DMD) adherence, which not only improves clinical outcomes but also reaps benefits when it comes to health care costs.

Transferring from pediatric to adult care can result in difficulties for patients with childhood-onset systemic lupus erythematosus.

In 2 studies of secukinumab use in real-world settings, researchers identified the usefulness of dose escalation in patients with psoriatic arthritis (PsA), as well as the safety, retention rate, and factors associated with drug survival among patients with PsA and ankylosing spondyloarthritis.

Umbilical cord blood provides a readily available source of stem cells to provide better access to hematopoietic stem cell transplantation to safely and effectively treat various noncancerous genetic disorders in children.

Two experimental vaccines, one from AstraZeneca and the other from CanSino Biologics, have shown promising results against coronavirus disease 2019 (COVID-19) in a phase 1/2 trial and a phase 2 trial. Results for both were published in The Lancet.

Although early diagnosis of axial spondyloarthritis is crucial for patients to receive timely access to care and effective treatment, these patients experience a diagnostic delay of more than 7 years, on average.

Researchers called for new guidance to address the underreporting of patient engagement in rare disease clinical trials after finding a dismal amount of patient-reported outcome measures listed in orphan drug labeling claims.

Two abstracts presented at the European Hematology Association's annual meeting evaluated the frequency of myeloid malignancies in patients with autoimmune disease and the impact autoimmune diseases have on patients with sickle cell disease.

Scientists do not yet have a full understanding of how multiple myeloma develops, but a new article suggests the gut microbiome is one factor that may play a role.

Treatment options for psoriatic arthritis and axial spondyloarthritis are increasing, and with studies already identifying response predictors for tumor necrosis factor inhibitors, there is a need to predict response to the interleukin-17A inhibitor secukinumab.

Patients with systemic lupus erythematosus (SLE) may consider hydroxychloroquine essential to their treatment, but after the drug was identified as a potential therapy for coronavirus disease 2019 (COVID-19), patients with SLE experienced reduced access to the treatment, which could increase the risk of SLE flare.

There are 3 key issues that, if addressed by Congress, can optimally assist medical groups and health systems dealing with financial struggles amid the pandemic. These include continued funding to the CARES Act Provider Relief Fund, reinstating the Medicare Accelerated and Advanced Payment program, and permanently lifting waivers on telehealth, said Jerry Penso, MD, MBA, president and CEO of the American Medical Group Association.

FDA has lifted a partial clinical hold on a phase 2 trial of a treatment for patients with relapsed or refractory (R/R) Hodgkin lymphoma from ADC Therapeutics. The trial of camidanlumab tesirine (Cami), an antibody drug conjugate that binds to CD25, is evaluating the safety and efficacy of the therapy and is intended to support the submission of a Biologics License Application to the FDA.